Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China · Delayed Price · Currency is CNY 10.90
+0.20 (1.87%)
May 19, 2026, 10:25 AM CST
SHE:301060 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,384 | 1,448 | 1,742 | 1,668 | 4,182 | 1,766 |
Other Revenue | - | - | 0.25 | 6.72 | 17.5 | 11.91 |
| 1,384 | 1,448 | 1,742 | 1,674 | 4,199 | 1,778 | |
Revenue Growth (YoY) | -16.44% | -16.88% | 4.05% | -60.13% | 136.14% | 43.62% |
Cost of Revenue | 1,029 | 1,101 | 1,410 | 1,345 | 2,420 | 1,105 |
Gross Profit | 355.45 | 346.98 | 332.53 | 329.31 | 1,779 | 672.9 |
Selling, General & Admin | 274.9 | 278.39 | 304.25 | 302.06 | 539.66 | 319.11 |
Research & Development | 37.98 | 41.05 | 59.97 | 48.86 | 109.4 | 39.44 |
Other Operating Expenses | -4.92 | -2.02 | 5.01 | 3.27 | 3.5 | 4.93 |
Operating Expenses | 307.97 | 317.42 | 394.9 | 484.87 | 708.33 | 378.75 |
Operating Income | 47.49 | 29.56 | -62.37 | -155.55 | 1,071 | 294.15 |
Interest Expense | - | - | -10.81 | -8.17 | -8.46 | -3.27 |
Interest & Investment Income | 7.8 | 6.44 | 10.63 | 5.58 | 3.53 | 8.93 |
Currency Exchange Gain (Loss) | - | - | -1.02 | -0.57 | -0.56 | 0.02 |
Other Non Operating Income (Expenses) | 19.02 | -8.8 | 1.52 | 0.99 | -0.05 | -0.21 |
EBT Excluding Unusual Items | 74.31 | 27.2 | -62.06 | -157.72 | 1,065 | 299.62 |
Impairment of Goodwill | - | - | - | -9.97 | -12.45 | - |
Gain (Loss) on Sale of Investments | - | 0.05 | -13.06 | -2.12 | 1.66 | 3.93 |
Gain (Loss) on Sale of Assets | -1.41 | -1.27 | 5.67 | 1.93 | -0.36 | -0.03 |
Asset Writedown | -9.32 | -15.45 | -17.14 | -1.26 | -115.07 | - |
Legal Settlements | - | - | -19.93 | -5.09 | - | - |
Other Unusual Items | - | - | 3.71 | 20.99 | -34.79 | 14.51 |
Pretax Income | 63.58 | 10.53 | -102.82 | -153.24 | 904.44 | 318.03 |
Income Tax Expense | 32.12 | 25.95 | -4.23 | 8.47 | 165.39 | 56.41 |
Earnings From Continuing Operations | 31.46 | -15.42 | -98.59 | -161.71 | 739.06 | 261.62 |
Minority Interest in Earnings | -17.21 | -15.32 | -10.85 | 20.12 | -121.73 | -57.78 |
Net Income | 14.25 | -30.75 | -109.44 | -141.59 | 617.32 | 203.84 |
Net Income to Common | 14.25 | -30.75 | -109.44 | -141.59 | 617.32 | 203.84 |
Net Income Growth | - | - | - | - | 202.85% | 84.68% |
Shares Outstanding (Basic) | 386 | 384 | 405 | 405 | 401 | 352 |
Shares Outstanding (Diluted) | 386 | 384 | 405 | 405 | 401 | 352 |
Shares Change (YoY) | -5.22% | -5.18% | 0.19% | 1.00% | 13.63% | 0.02% |
EPS (Basic) | 0.04 | -0.08 | -0.27 | -0.35 | 1.54 | 0.58 |
EPS (Diluted) | 0.04 | -0.08 | -0.27 | -0.35 | 1.54 | 0.58 |
EPS Growth | - | - | - | - | 166.52% | 84.64% |
Free Cash Flow | 318.9 | 210.36 | 139.7 | 148.1 | -145.91 | 104.63 |
Free Cash Flow Per Share | 0.83 | 0.55 | 0.34 | 0.37 | -0.36 | 0.30 |
Dividend Per Share | - | - | 0.200 | - | 0.300 | 0.300 |
Gross Margin | 25.68% | 23.96% | 19.09% | 19.67% | 42.37% | 37.84% |
Operating Margin | 3.43% | 2.04% | -3.58% | -9.29% | 25.50% | 16.54% |
Profit Margin | 1.03% | -2.12% | -6.28% | -8.46% | 14.70% | 11.46% |
Free Cash Flow Margin | 23.04% | 14.53% | 8.02% | 8.85% | -3.48% | 5.88% |
EBITDA | 115.97 | 96.28 | -2.73 | -106.34 | 1,133 | 338.96 |
EBITDA Margin | 8.38% | 6.65% | -0.16% | -6.35% | 26.98% | 19.06% |
D&A For EBITDA | 68.49 | 66.72 | 59.64 | 49.21 | 62.21 | 44.82 |
EBIT | 47.49 | 29.56 | -62.37 | -155.55 | 1,071 | 294.15 |
EBIT Margin | 3.43% | 2.04% | -3.58% | -9.29% | 25.50% | 16.54% |
Effective Tax Rate | 50.52% | 246.44% | - | - | 18.29% | 17.74% |
Revenue as Reported | - | - | 1,742 | 1,674 | 4,199 | 1,778 |
Advertising Expenses | - | - | 0.79 | 0.9 | 3.2 | 3.39 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.